Zerbaxa
MSD announces phase 2 results for tulisokibart in moderate to severe hidradenitis suppurativa
Tulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in HS
MSD and Moderna announce potential new vaccine for melanoma
The mRNA-based therapy, used with Keytruda, is designed specifically for each patient
Gilead’s Trodelvy plus Keytruda shows positive results in metastatic breast cancer
The combination treatment showed a 35% reduction in the risk of disease progression
David Weinreich appointed as Merck’s Global Head of R&D and CMO, Healthcare
Weinreich will be based in Billerica, Massachusetts at the company’s Research and Development site
MSD receives NICE recommendation for Keytruda in advanced endometrial cancer
More than 9,700 new cases of endometrial cancer are diagnosed every year in the UK
Merck unveils $3bn cost-cutting plan to support pipeline and new product launches
A new restructuring programme has been approved to support the initiative
Merck’s perioperative Keytruda regimen approved by FDA for head and neck cancer
More than 72,680 new cases of the disease are expected to be diagnosed in the US this year
Merck shares promising phase 3 results for Keytruda in ovarian cancer
Approximately 20,890 cases of the disease are expected to be diagnosed in the US this year
MSD receives MHRA approval for adult-specific pneumococcal vaccine Capvaxive
Illnesses caused by Streptococcus pneumoniae are currently considered a major public health problem by WHO
Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer
Triple-negative breast cancer accounts for approximately 15% of all cases of the disease
Merck gains rights to Hengrui’s heart disease candidate in deal worth almost $2bn
Cardiovascular diseases result in an estimated 17.9 million global deaths each year
Pfizer/Astellas share positive phase 3 results for Padcev in bladder cancer
Approximately 614,000 people are diagnosed with bladder cancer globally every year